Direkt zum Inhalt
Merck
  • A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine.

A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine.

Seizure (2005-02-08)
Ewa B Posner, Khalid Mohamed, Anthony G Marson
ZUSAMMENFASSUNG

To evaluate the role of ethosuximide, sodium valproate and lamotrigine in children and adolescents with typical absence seizures (AS). A systematic review of randomized controlled trials that included children or adolescents with typical absence seizures who received treatment with ethosuximide, sodium valproate or lamotrigine. Four RCTs fulfilled the inclusion criteria. Due to the heterogeneity of the studies the results could not be pooled in a meta-analysis. We found no reliable evidence to inform clinical practice. The design of further trials should be pragmatic and compare one drug with another.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Ethosuximid
Supelco
Ethosuximid, Pharmaceutical Secondary Standard; Certified Reference Material
Ethosuximid, European Pharmacopoeia (EP) Reference Standard